Protara Therapeutics is a clinical-stage biopharmaceutical company focused on identifying and developing transformative therapies for the treatment of cancer and rare diseases. Co.'s primary oncology program is TARA-002 in non-muscle invasive bladder cancer. Co. is also pursuing TARA-002 in lymphatic malformations, which are rare, non-malignant cysts of the lymphatic vascular system. The third development program in Co.'s portfolio is intravenous Choline Chloride, an investigational phospholipid substrate replacement therapy initially in development for patients receiving parenteral nutrition, who have intestinal failure associated liver disease. The TARA stock yearly return is shown above.
The yearly return on the TARA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TARA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|